Pierre Fenaux

发表

ERN-EurobloodNet: A European Reference Network for Rare Blood Diseases and a Model for Emulation

Pierre Fenaux, Béatrice Gulbis, María del Mar Mañú Pereira, 2019 .

Revised international prognostic scoring system for myelodysplastic syndromes.

Luca Malcovati, Pierre Fenaux, Mario Cazzola, 2012, Blood.

Inflammatory Arthritis in Patients With Myelodysplastic Syndromes

Pierre Fenaux, David Launay, O. Decaux, 2014, Medicine.

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Claude Preudhomme, Pierre Fenaux, C. Preudhomme, 2002, Blood.

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.

Pierre Fenaux, R. Stone, P. Fenaux, 2007, Blood.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Bob Löwenberg, Benjamin L Ebert, Pierre Fenaux, 2017, Blood.

Review Articles (434 articles)

Bob Löwenberg, Pierre Fenaux, Hartmut Döhner, 2008 .

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Benjamin L. Ebert, Michael R. Savona, John M. Bennett, 2019, Nature Medicine.

Valuation of transfusion-free living in MDS: results of health utility interviews with patients

Pierre Fenaux, Michael Lübbert, T. Goss, 2009, Health and quality of life outcomes.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.